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Background/Aims: To reveal possible factors predicting the 
effect of adefovir dipivoxil (ADV) treatment on chronic hepa-
titis B (CHB) and optimize the utilization of ADV. Methods: 
In total, 168 treatment-naïve CHB patients were enrolled, 
including 117 hepatitis B e antigen (HBeAg)-positive patients 
and 51 HBeAg-negative patients who met the inclusion cri-
teria. All patients were treated with ADV 10 mg per day for 
48 weeks. Multiple logistic regression analyses were used 
to investigate baseline factors, and responses at weeks 12 
and 24 were analyzed as predictive values. Results: Multiple 
regression analyses showed that baseline HBeAg status and 
HBV DNA levels signiﬁ  cantly affected the virological response 
(VR) (p<0.05), baseline ALT levels were an independent pre-
dictor of serological response (SR) (p<0.05) and the body 
mass index (BMI) may affect the biochemical response (BR) 
(p<0.05). There was a statistically significant difference in 
the VR and SR between patients with a primary nonresponse 
(PNR) at week 12 and those with a VR at week 12 (p<0.01). 
Additionally, the VR was significantly different between 
patients with HBV DNA lower than 10
3 copies/mL at week 
24 and those with greater than 10
3 copies/mL (p<0.01). 
Conclusions: Patients with negative HBeAg, lower HBV DNA 
levels and higher ALT values at baseline are more suitable 
for ADV treatment, whereas patients with lower BMIs may be 
more amenable to ALT normalization. Adjustments for treat-
ment strategy should be considered if PNR at week 12 or 
HBV DNA ≥10
3 copies/mL at week 24 is observed. (Gut Liver 
2011;5:478-485)
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INTRODUCTION
In recent years, multiple evidences confirmed that antiviral 
treatment with nucleoside analogues of chronic hepatitis B (CHB) 
could inhibit viral replication, improve liver function, reduce the 
incidence of decompensated liver diseases, including cirrhosis 
and liver cancer, and thus improve the prognosis of diseases.
1 
With progressive scope in clinical application and research in 
this field, philosophy of antiviral therapy has transformed from 
simple application with a personal preference to optimization 
therapy, including determination of the most favorable target 
population, option of initial drug, adjustment followed by re-
sponse, management for drug resistance, combination or se-
quential treatment, etc.
2-4 
Among 4 available nucleoside analogues in China,
5 adefovir 
dipivoxil (ADV) has been widely used for the treatment of CHB 
due to its abilities to reduce the viral load, normalize the liver 
function, improve the liver histology, and show a few side ef-
fects and due to its cost effectiveness and low occurrence rate 
of drug-resistance after long-term use.
6,7 However, different 
responses of ADV on CHB patients were found in clinical prac-
tice, and some of them showed unsatisfactory effects such as 
primary nonresponse (PNR) or partial response. The efficacy of 
drugs was affected both by the virus and host factors. Therefore, 
it is very important to analyze predictive factors for the effect 
of ADV so as to optimize its effects including screening more 
qualified patients at beginning of treatment, adjusting treatment 
strategy according to some useful valuable indicators during 
the treatment. However, as clinical data about predictive factors 
during the treatment for the efficacy of ADV are mainly from 
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py in naïve CHB patients are rare, and the effect-related factors 
remain still unclear.
In this study, a total of 168 naïve CHB patients who received 
ADV monotherapy for 48 weeks, were enrolled and a prelimi-
nary investigation on possible predictive factors for the effect 
of ADV was carried out to provide the grounds for optimization 
therapy.
MATERIALS AND METHODS
1. Patients and study design
This study was performed by retrospective chart review. Pa-
tients who visited the outpatient clinic of West China Hospital 
of Sichuan University from March 2007 to June 2008 and met 
the inclusion criteria were enrolled in this study. The inclusion 
criteria were as follows: positive for hepatitis B surface antigen 
(HBsAg) for at least 6 months and without history of antivirus 
therapy with nucleoside analogues; alanine aminotransferase 
(ALT) levels between 2 to 10 times the upper normal levels; HBV 
DNA levels ≥10
5 copies/mL for hepatitis B e antigen (HBeAg)-
positive patients and ≥10
4 copies/mL for HBeAg-negative pa-
tients. Patients were excluded if coinfected with HIV and other 
hepatitis viruses, nonalcoholic fatty liver disease, alcoholic liver 
disease, post-hepatic cirrhosis and hepatocellular carcinoma. 
The diagnosis of fatty liver depends on characteristic arise of 
liver enzymes including γ-glutamyltransferase, change of ul-
trasound Doppler and other underlying diseases with metabolic 
disorder.
8 Diagnosis of alcoholic liver disease depends on alco-
hol consumption, drinking life and special imaging examination 
including ultrasound Doppler and/or computed tomography 
(CT).
9 Liver cirrhosis can be confirmed through invasive and 
noninvasive techniques including liver stiffness measurement, 
special imaging examination and liver biopsy.
10 Hepatocellular 
carcinoma also can be diagnosed by elevated A fetal protein 
and characteristic imaging manifestation including CT and/or 
magnetic resonance imaging (MRI).
11
All patients were given ADV 10 mg daily as antiviral treat-
ment for at least 48 weeks (mean duration of treatment was 52 
weeks). Patients who discontinued medication before 48 weeks 
were not included in this study. During the treatment period, 
patients were not given any other antiviral drugs and medicines 
for liver function protection. 
2. Serum assays
Analyses of liver and renal functions, which included serum 
levels of total bilirubin (TB), ALT, albumin, blood urea nitro-
gen (BUN), creatine, and serum electrolyte, were performed at 
baseline, and at weeks 12, 24, 36, and 48 of ADV treatment, 
using the Automatic Biochemistry analyzer (Olympus AU5400; 
Olympus Co., Tokyo, Japan). Statuses of HBsAg, HBeAg, and 
antibodies to HBeAg (anti-HBe) were measured by a micropar-
ticle enzyme-linked immunosorbent assay at baseline, and 
weeks 24 and 48. Serum HBV DNA was quantified by real-time 
polymerase chain reaction (LightCycler480; Roche Diagnostics, 
Mannheim, Germany) at baseline and weeks 12, 24, 36, and 48, 
with a linear range between 1×10
3 and 5×10
7 copies/mL (Da An 
Gene Co., Ltd. of Sun Yat-Sen University, Guangzhou, China). 
ADV-associated mutations were assessed via direct sequencing 
if virological breakthrough occurred during the treatment. All 
assays were performed in microbiological laboratories in West 
China Hospital of Sichuan University.
3. Deﬁ  nition and evaluation of efﬁ  cacy
Virological response (VR) was defined as a reduction of HBV 
DNA levels to less than detection level (<10
3 copies/mL). Bio-
chemical response (BR) was defined as a normalization of ALT 
levels. Serological response (SR) was defined as disappearance 
of HBeAg with or without the appearance of HBeAb. PNR was 
defined as a decline less than 1 log of HBV DNA levels at week 
12 of the treatment according to EASL Clinical Practice Guide-
lines of 2009.
12 Non PNR was defined in comparison with PNR 
as a decline more than 1 log of HBV DNA levels at week 12 of 
the treatment. Virological breakthrough was defined as a >1 log 
copies/mL increase in serum HBV DNA compared to the on-
treatment nadir that was confirmed in 2 consecutive tests. Drug 
resistance (DR) was defined as the emergence of virological 
breakthrough and presence of drug resistance mutations.
The antiviral efficacy of ADV was assessed at weeks 12, 24, 
and 48 during treatment. Rates of VR, BR, SR, PNR, and DR 
were assessed at the above mentioned time points respectively. 
Baseline factors including age, gender, body mass index (BMI), 
HBeAg status, ALT, and DNA levels were analyzed for their 
influence on the effect of ADV treatment. PNR at week 12 and 
HBV DNA levels at week 24 were analyzed as predictive factors 
during the treatment. 
4. Statistical analysis
Quantitative data were presented as the mean±standard devi-
ation, categorical data were presented as counts and percentag-
es, and HBV DNA levels were presented as log transformation. 
Data were analyzed using the SPSS software package version 
13.0 (SPSS Inc., Chicago, IL, USA). Pearson chi-square or Fisher 
exact tests were used for categorical variables. Logistic regres-
sion analysis was used to investigate the baseline predictors for 
the response of treatment. In all cases, tests of significance were 
two-tailed, and significance was defined for p<0.05.
RESULTS
1. General information
A total of 168 patients were included, consisted of 119 
(70.83%) males and 49 (29.17%) females, with ages ranging 
from 18 to 45 years (mean, 29.92±6.78 years) and BMI ranging 
from 17.22 to 27.34 (mean, 21.64±1.83). Baseline data were as 480  Gut and Liver, Vol. 5, No. 4, December 2011
follows: for 117 HBeAg-positive patients, the median level of 
HBV DNA was 5.00×10
7 copies/mL and the mean level of ALT 
was 197.58±110.93 IU/mL; for 51 HBeAg-negative patients, 
the median level of HBV DNA was 1.76×10
6 copies/mL and the 
mean level of ALT was 171.23±125.83 IU/mL.
2. Virological effect
Of the 117 HBeAg-positive patients, reduction of HBV DNA 
level was 2.13±1.31, 2.79±1.23, and 3.22±1.16 lg copies/mL 
at weeks 12, 24, and 48 respectively compared with that of 
the baseline; and VR was observed in 7.69% (9/117), 17.95% 
(21/117), and 28.21% (33/117) of patients at weeks 12, 24, and 
48, respectively. 
Of the 51 HBeAg-negative patients, reduction of HBV DNA 
level was 2.32±1.17, 2.81±1.04, and 3.00±1.12 lg copies/mL at 
weeks 12, 24, and 48 respectively compared with that of the 
baseline; and VR was observed in 17.65% (9/51), 52.94% (27/51), 
and 62.75% (32/51) of patients at weeks 12, 24, and 48, respec-
tively.
3. Biochemical effect
Of the 117 HBeAg-positive patients, ALT normalization was 
achieved in 42.74% (50/117), 67.52% (79/117), and 87.18% 
(102/117) at weeks 12, 24, and 48, respectively. 
Of the 51 HBeAg-negative patients, ALT normalization was 
achieved in 64.71% (33/51), 74.51% (38/51), and 88.24% (45/51) 
at weeks 12, 24, and 48, respectively. 
4. Serological effect
Of the 117 HBeAg-positive patients, the disappearance of 
HBeAg was observed in 10.26% (12/117) and 43.59% (51/117) 
of patients at weeks 24 and 48, respectively. An HBeAg/anti-
HBe seroconversion was achieved in 5.13% (6/117) and 15.38% 
(18/117) of patients at weeks 24 and 48, respectively.
5. PNR
For HBeAg-positive patients at week 12, the rate of PNR was 
20.51% (24/117). And for HBeAg-negative patients at week 12, 
the rate of PNR was 11.76% (6/51) (Fig. 1). 
6. Resistance and side effects
By week 48, no virus breakthrough occurred in all patients. 
Overall, ADV demonstrated a good safety profile. All levels of 
serum electrolytes were normal. Mild adverse reactions were 
observed only in 5 (2.98%) patients, including 4 patients with 
a transient mild increase of BUN. The patients were monitored 
closely and no other drugs were given, and BUN value returned 
to normal level gradually. Another patient suffered from insom-
nia symptom, which disappeared after symptomatic treatment.
7. Logistic regression analysis of baseline impact factors 
for antiviral effect of ADV
If VR at week 48 was regarded as outcome variable, the re-
sults of multiple logistic regression analyses of factors at base-
line showed that baseline HBeAg status and baseline HBV DNA 
level were independent factors of week 48 VR (p<0.05). Values 
of odds ratio (OR) showed that it was easier to achieve unde-
tectable HBV DNA level at week 48 in patients with negative-
HBeAg and lower HBV DNA levels compared with patients with 
Fig. 1. Comparison of responses between patients with primary non-
response (PNR) at week 12 and patients with nonPNR at week 12.
BR, biochemical response; SR, serological response; VR, virological 
response. *p<0.05.
Table 1. Analyses with VR at Week 48 as the Outcome Variable
Baseline factor β SE Df p-value OR 95% CI
Age 0.061 0.037 1 0.123 1.062 0.986–1.153
Gender -0.868 0.465 1 0.075 0.420 0.153–1.062
BMI -0.234 0.139 1 0.094 0.791 0.597–1.041
HBeAg status 1.118 0.461 1 0.021 3.059 1.130–7.596
HBV DNA 0.111 0.102 1 0.031 1.697 1.015–3.256
ALT 0.001 0.002 1 0.673 1.001 0.997–1.005
VR, virological response; β, coefficient; SE, standard error; Df, degree of freedom; OR, odds ratio; CI, confidence interval; BMI, body mass index; 
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positive-HBeAg and higher HBV DNA levels at baseline (Table 1).
If BR at week 48 was regarded as outcome variable, the re-
sults of multiple logistic regression analyses of factors at base-
line showed that BMI was an independent factor of week 48 BR 
(p<0.05). Values of OR showed that it was easier to achieve the 
normalization of ALT at week 48 in patients with lower BMI 
compared with patients with higher BMI at baseline. The results 
also showed that both baseline HBeAg status and baseline HBV 
DNA level were not impact factors for BR (Table 2).
When SR at week 48 was regarded as outcome variable, the 
results of multiple logistic regression analyses of factors at base-
line showed that baseline ALT level was an independent factors 
of week 48 SR (p<0.05). Values of OR showed that it was easier 
to achieve the HBeAg disappearance at week 48 in patients with 
higher ALT levels compared with patients with lower ALT level 
at baseline. The results also show that both baseline HBeAg sta-
tus and baseline HBV DNA level were not impact factors on SR 
(Table 3).
8. The PNR of week 12 as predictive factor during treat-
ment for efﬁ  cacy of week 48
For 30 patients with PNR at week 12, the rates of VR, BR, 
and SR at week 48 were 10% (3/30), 83.33% (25/30), and 8.33% 
(2/24), respectively. But for the other 138 patients with non PNR 
at week 12, the rates of VR, BR, and SR at week 48 were 44.93% 
(62/138), 88.41% (122/138), and 52.69% (49/93), respectively. 
The difference in VR and SR between the 2 groups was statisti-
cal significant (p=0.004, p=0.001), but similar in BR (p=0.816).
9. The rate of HBV DNA <10
3 copies/mL at weeks 12 and 
24 as predictive factor during treatment for efﬁ  cacy of 
week 48
For 18 patients with HBV DNA <10
3 copies/mL at week 12, 
the rates of VR, BR, and SR at week 48 were 100% (18/18), 
83.33% (15/18), and 44.44% (4/9), respectively. But for the 
other 150 patients with HBV DNA ≥10
3 copies/mL at week 12, 
the rates of VR, BR, and SR at week 48 were 31.33% (47/150), 
Table 2. Analyses with BR at Week 48 as Outcome Variable
Baseline factor β SE Df p-value OR 95% CI
Age -0.027 0.042 1 0.625 0.973 0.869–1.083
Gender -0.599 0.633 1 0.420 0.549 0.126–2.299
BMI 0.407 0.164 1 0.045 1.503 1.006–2.243
HBeAg status -0.681 0.118 1 0.343 0.506 0.112–1.997
HBV DNA 0.000 0.533 1 0.286 0.591 0.280–1.771
ALT -0.002 0.003 1 0.577 0.998 0.992–1.004
BR, biochemical response; β, coefficient; SE, standard error; Df, degrees of freedom; OR, odds ratio; CI, confidence interval; BMI, body mass index; 
HBeAg, hepatitis B e antigen; DNA, deoxyribonucleic acid; ALT, alanine aminotransferase.
Table 3. Analyses with SR at Week 48 as Outcome Variable
Baseline factor β SE Df p-value OR 95% CI
Age 0.013 0.034 1 0.772 1.013 0.918-1.055
Gender -0.620 0.447 1 0.262 0.538 0.289-1.697
BMI -0.017 0.131 1 0.908 0.983 0.724-1.202
HBV DNA 0.000 0.098 1 0.389 0.762 0.572-1.408
ALT -0.006 0.002 1 0.015 0.994 0.991-0.999
SR, serological response; β, coefficient; SE, standard error; Df, degrees of freedom; OR, odds ratio; CI, confidence interval; BMI, body mass index; 
DNA, deoxyribonucleic acid; ALT, alanine aminotransferase.
Fig. 2. Comparison of responses between patients with HBV DNA 
<10
3 copies/mL and patients with HBV DNA ≥10
3 copies/mL at week 
12. 
HBV, hepatitis B virus; VR, virological response; BR, biochemical re-
sponse; SR, serological response. *p<0.05.482  Gut and Liver, Vol. 5, No. 4, December 2011
88% (132/150), and 43.52% (47/108), respectively. Between 
the 2 groups the difference in VR was statistically significant 
(p<0.001), but not statistically significant in BR and SR (p=1.000) 
(Fig. 2).
For 48 patients with HBV DNA <10
3 copies/mL at week 24, 
the rates of VR, BR, and SR at week 48 were 100% (48/48), 
83.33% (40/48), and 71.44% (15/21), respectively. But for the 
other 120 patients with HBV DNA ≥10
3 copies/mL at week 24, 
the rates of VR, BR, and SR at week 48 were 14.17% (17/120), 
89.17% (107/120), and 37.5% (36/96), respectively. The differ-
ences in both VR and SR between the 2 groups were statistically 
significant (p<0.001, p=0.02), but were not statistically signifi-
cant in BR (p=0.895) (Fig. 3).
DISCUSSION
The importance of optimization therapy of nucleoside ana-
logues relies in its long-term treatment course and inevitable 
resistance occurrence. It is widely debated on how to screen 
patients who are the most qualified target population for cer-
tain drugs. During the therapy, efficacy predictions are usually 
performed to achieve the best effect, the lowest resistance oc-
currence and the highest effect-cost ratio. In recent years, opti-
mization therapy of nucleoside analogues focused on the issues 
of baseline situation, considering early response and application 
of roadmaps.
13
Due to its antiviral effect, lower drug-resistance, affordable 
price and no cross-resistance with other nucleoside analogues, 
ADV is still widely used in naïve CHB patients in certain coun-
tries including China and Asia. Although ADV was no longer 
included in 2009 EASL and AASLD guidelines as choice of first-
line antiviral therapy,
14 its usage is estimated to continue in 
many countries including China, as tenofovir will not be avail-
able in the next several years in these countries and it is much 
cheaper than Entecavir. Therefore research on predictive factors 
of antiviral efficacy of ADV is still important and would provide 
us better evidence for optimization therapy.
In this study, 168 cases of CHB patients who received at 
least 48 weeks’ ADV treatment were included. The rates of VR, 
BR, and SR of 117 patients with positive HBeAg were 28.21%, 
87.18%, and 43.59% after 48 weeks of treatment, respectively. 
The rates of VR and BR of 51 patients with negative HBeAg 
were 62.75% and 88.24%, respectively. These results suggest 
that the VR in HBeAg-negative patients were obviously higher 
than HBeAg-positive patients, but similar in BR. The results 
were similar and in accordance with other published data,
15,16 
but extent of virus reduction and VR rate were not as impres-
sive as previously reported.
17-19 The possible reason may be due 
to the high baseline of HBV-DNA levels, with 5.00×10
7 copies/
mL median levels of HBV DNA. At the same time, virological 
breakthrough did not occur in patients with 48 weeks’ therapy, 
ADV was well tolerated in all patients, and rate of adverse reac-
tion was only 2.98%.
The present study investigated several baseline host and viral 
factors that may influence the antiviral efficacy, including age, 
gender, BMI, baseline HBeAg status, baseline HBV DNA and 
ALT levels. The results of multiple regression statistical analyses 
show that both the patient’s age and gender had no impact on 
the VR, BR, and SR. With regard to BMI, it has been reported 
that sustained response of indinavir and saquinavir was related 
to weight in AIDS studies.
20 However, it has not been confirmed 
that the body weights were associated with VR in hepatitis C or 
hepatitis B.
21 In this study, the relationship between VR, SR, and 
BMI was also not confirmed. It means that higher BMI didn’t 
show less effective viral suppression or not. Yet, it seems that 
BMI may influence BR, and the clinical significance of this con-
clusion is still worthy to be confirmed by further studies. 
The results suggest that baseline HBeAg status and HBV 
DNA level significantly affected VR; especially higher VR was 
observed in patients with HBeAg-negative and lower HBV 
DNA at baseline. These results were similar to several previ-
ous reports,
22,23 and confirmed again that the curative effect of 
HBeAg-negative patients with lower baseline HBV DNA is su-
perior to the effect of HBeAg-positive patients with higher HBV 
DNA. However, contradictory to other reports,
19 results of this 
study suggest that baseline ALT levels couldn’t influence VR at 
week 48. The possible reason may be related to a close and little 
range of ALT levels and a small dispersion of patients in this 
group. The results showed that baseline HBeAg statues, baseline 
HBV DNA and ALT levels had no effect on BR. The results of 
influencing factors analysis of SR showed that the occurrence 
of E-antigen disappearance or seroconversion was not signifi-
cantly correlated with baseline HBV DNA, which was different 
with data a published by Tseng et al.
24 However, the results 
Fig. 3. Comparison of responses between patients with HBV DNA 
<10
3 copies/mL and patients with HBV DNA ≥10
3 copies/mL at week 
24. 
HBV, hepatitis B virus; VR, virological response; BR, biochemical re-
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show a correlation between baseline ALT levels and SR. Patients 
with higher ALT levels at baseline achieved disappearance or 
seroconversion of HBeAg easier. A possible interpretation is that 
higher baseline ALT levels suggest a strong immune response, 
which facilitates the reconstruction of a specific immune re-
sponse against HBV, thereby inhibiting the expression of HBeAg 
and promoting anti-HBe production. Yet, it is worth mentioning 
that as the observation period of this study lasted for only 48 
weeks, the statistical conclusions of this study are limited and a 
long-term follow-up is needed. 
Many studies suggest that genotype only affects the response 
of interferon therapy, but do not play a role in nucleoside ana-
logues.
25-27 At the same time, the genotype determination in our 
country has not yet been widely used in clinical practice, such 
as in this study the correlation between the genotype and anti-
viral efficacy was not analyzed.
In this study, the predictive value of PNR at week 12 on effect 
of 48 weeks’ therapy was analyzed. The results showed that the 
VR at week 48 were 10% and 44.3% respectively for patients 
with PNR and with nonPNR at week 12, and the difference in 
VR was statistically significant. At the same time, the difference 
in SR was also significant (8.33% vs. 52.69%). These results 
suggest that only 10% of patients with PNR at week 12 acquired 
VR at week 48, and only 8.33% acquired SR. Therefore, if PNR 
is observed at week 12, treatment strategies should be adjusted, 
including adding-on or switching to other agents. This point of 
view is similar to that of Hass et al.
28
On the other hand, this study also discusses the predictive 
value of HBV DNA <10
3 copies/mL at weeks 12 and 24 for VR, 
BR, and SR of week 48. The results show that the difference in 
48 weeks’ BR and SR was not statistically significant between 
patients with HBV DNA <10
3 copies/mL at week 12 and those 
HBV DNA ≥10
3 copies/mL. However, a significant difference of 
100% and 31.33% respectively was seen in VR. If the analysis 
was performed at week 24, the VR of the 2 groups were 100% 
and 14.17%, respectively, while difference in SR was also sig-
nificant (71.44% vs. 37.5%). It can be seen that HBV DNA <10
3 
copies/mL at weeks 12 and 24 is a strong predictor of response, 
and is especially important for predicting VR at week 48. These 
results are also similar to other published reports.
29,30 Yet, which 
time point has a higher predictive value, week 12 or week 24? 
The results of this study suggest that 31.33% of patients with 
HBV DNA ≥10
3 copies/mL at week 12 could still achieve VR at 
week 48, but if HBV DNA was still ≥10
3 copies/mL at week 24, 
only 14.17% patients were able to achieve VR at week 48, with 
a significant difference in SR between HBV DNA ≥10
3 copies/
mL and HBV DNA <10
3 copies/mL at week 24. So the results 
of this study suggest that treatment strategies should be as-
sessed and adjusted at week 24 instead of week 12 according to 
whether HBV DNA level had reduced to lower than 10
3 copies/
mL. Strategies such as adding-on or switching to other agents 
can be considered. 
Of the 168 cases in this study, no virological breakthrough 
was observed. However, the observation period lasted only 48 
weeks. With the extension of treatment course, the occurrence 
of drug-resistance may increase gradually. Therefore, it is nec-
essary to monitor the occurrence of drug resistance with ongo-
ing treatment. At the same time, even though the incidence of 
adverse reactions of ADV in the study was low and therapy 
could be applied also for children,
31 it is necessary to monitor 
the kidney function closely,
32 particularly in kidney transplant 
patients
33 due to its kidney damage potential. Additionally, the 
incidence of hypolipidemia with low phosphate should be con-
sidered.
34
In summary, our results suggest the following conclusions: 
ADV has efficacy in CHB patients, with a good safety profile 
and no resistance at week 48. In particular, patients with nega-
tive HBeAg, lower HBV DNA level and higher ALT values at 
baseline would be more suitable for ADV therapy, while patients 
with lower BMI may have some advantages on ALT normaliza-
tion. On the other hand, during the course of treatment, it is 
crucial to focus on the response of weeks 12 and 24. In case a 
PNR is seen at week 12 or >10
3 copies/mL at week 24, alteration 
or adjustment of treatment strategy should be considered.
The primary limitations of this study lie in the relatively short 
observation time period and the small number of patients. In 
addition, our HBV DNA assay has limited dynamic range only 
between 1×10
3 and 5×10
7 copies/mL. This limits accurate as-
sessment of antiviral efficacy of adefovir in this study. However, 
the results of this study suggest some clues and indicators with 
clinical value in 48 weeks’ observation period. Further studies 
continuing treatment for longer terms with more improved HBV 
DNA assay allowing wider detection limits are warranted.
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